The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab conveys almost double the cardio-protective benefit in patients with diabetes following acute coronary syndrome than those without diabetes, a large international trial has shown.

The study, funded by Sanofi and Regeneron Pharmaceuticals, also suggests that an aggressive lipid-lowering treatment with an LDL cholesterol concentration target of 0.65-1.30mmol/L does not increase the risk of new-onset diabetes, the researchers say.